0001762359 false 0001762359 2022-03-01 2022-03-01 0001762359 acrg:ClassESubordinateVotingSharesMember 2022-03-01 2022-03-01 0001762359 acrg:ClassDSubordinateVotingSharesMember 2022-03-01 2022-03-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 1, 2022

 

ACREAGE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
Commission File Number: 000-56021
 
British Columbia, Canada 98-1463868
(State or other jurisdiction of incorporation) (IRS Employer Identification No.)
   

450 LEXINGTON AVENUE, #3308

NEW YORK, New York, 10163, united states

(Address of principal executive offices, including zip code)
 
(646) 600-9181
(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class E subordinate voting shares     ACRHF   OTC Markets Group Inc.  
         
Class D subordinate voting shares   ACRDF   OTC Markets Group Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Chief Operating Officer

 

On March 1, 2022, Acreage Holdings, Inc. (the “Company”) announced the appointment of Dennis Curran as the Chief Operating Officer, effective the same date. Mr. Curran is replacing Robert J. Daino, who previously announced his decision on October 26, 2021 to retire as the Chief Operating Officer, effective as of March 31, 2022.

 

Mr. Curran, 57, previously served as Chief Customer Officer of GSK Consumer Healthcare, a consumer healthcare company and developer of healthcare brands and products, from 2015 to 2022, where he was responsible for delivering sales, profitability, and innovation for the United States, the business’ largest market. Prior to that, Mr. Curran had a 29-year career at Procter and Gamble, working in both the United States and Europe with some of the world’s leading consumer brands. In his last role at Proctor and Gamble, Mr. Curran served as the Regional Manager and President for P&G’s North American Prestige business, from 2012 to 2015, where he was responsible for overseeing sales, marketing, operations, and communications for various prestige brands with a portfolio worth roughly $550 million. In this role, he was also responsible for launching major product news on each brand twice per year and creating the re-entry of certain brands in the United States.

 

The Company has entered into an offer letter (the “Offer Letter”) with Mr. Curran with respect to his employment as Chief Operating Officer. The Offer Letter provides for Mr. Curran to receive: (a) an annual base salary of $350,000; (b) an initial equity award under the Acreage Holdings, Inc. Annual Omnibus Equity Incentive Plan with a total value of up to $1,050,000 (the “Equity Award”); and (c) a Short Term Incentive bonus award, targeted to be 75% of Mr. Curran’s base salary with the opportunity to increase to 150% of Mr. Curran’s base salary based on the satisfaction of certain Company financial performance targets. The Equity Award will vest annually in one-third increments and consists of New Restricted Stock Units and Floating Restricted Stock Units (“RSUs”) and New Options and Floating Options (“Options”), the final type and amount to be determined by the Board of Directors of the Company with the total number of RSUs and Options to be equal to $1,050,000 divided by the closing price of the Company’s common stock on the Canadian Securities Exchange on March 1, 2022. The Offer Letter also provides severance benefits equal to twelve months of Mr. Curran’s base salary following his termination by the Company without cause.

 

There are no arrangements or understandings with any other person pursuant to which Mr. Curran will be appointed as the Company’s Chief Operating Officer, and there are no family relationships between Mr. Curran and any director or executive officer of the Company. Additionally, there are no transactions between Mr. Curran and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

 

A copy of the Offer Letter is filed with this Current Report on Form 8-K as Exhibit 10.1 and the Company’s press release announcing the appointment of Mr. Curran is attached hereto as Exhibit 99.1. The foregoing description of the terms of the Offer Letter is a summary of select terms, is not complete, and is qualified in its entirety by reference to the full text thereof, which is incorporated by reference herein.

 

 

 

 

Appointment of New Director

 

On March 3, 2022, the Company announced that Steven Strom has been appointed to the Company’s Board of Directors.

 

Mr. Strom is the founder of Odinbrook Global Advisors and has more than thirty years of experience advising companies in the US, Canada, Latin America, Europe and Asia. Mr. Strom focuses on providing expert advice to clients to develop restructuring strategies and implement solution transactions. Mr. Strom served as a director for Schmitt Industries Inc. (NASDAQ:SMIT) from June 2019 to October 2021 and since May 2020, he has served as the chairman of the audit committee and board member of Dayco. From 2016 to early 2018 Mr. Strom was CEO of Blackhill Partners, an investment bank based in Dallas, Texas. Previously, he was a Managing Director in the Restructuring Group at Jefferies where he joined in 2006 and was Global Head of Restructuring from 2008 to 2014. Prior to Jefferies, Mr. Strom was a Managing Director in the Restructuring Group at CIBC World Markets (2002-2006) and a Managing Director at Chanin Capital Partners (1997-2002), a Research Analyst/Trader at Commodities Corporation (1993-1996) and a Vice President in the M&A Group at Chemical Bank (1986-1993). Mr. Strom has an MBA with a concentration in Finance from the University of Michigan (1986) and a bachelor’s degree in Business (Finance) from Arizona State University (1984) where he had a Regent’s Academic Scholarship and was awarded the Outstanding Finance Student by the Financial Analysts Society.

 

As a non-employee director, Mr. Strom will receive a new director bonus of $150,000 of restricted stock units, or RSUs, and annual compensation consistent with that paid to other non-employee directors as determined yearly.

 

There is no arrangement or understanding between Mr. Strom and any other person pursuant to which Mr. Strom was appointed as a director of the Company, and there are no transactions in which Mr. Strom has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

Mr. Strom was appointed by the Board to fill a vacancy created by the Board when it increased the size of its Board from eight to nine directors pursuant to its authority to determine the size of the Board as granted to it under the Articles of Incorporation.

 

The Company’s press release announcing the appointment of Mr. Strom is attached hereto as Exhibit 99.2 and is incorporated herein by reference into this Item 5.02.

 

Item 9.01. Financial Statements and Exhibits.
   
(d) Exhibits. The following exhibits are filed as part of this Current Report on Form 8-K.
   
Exhibit No. Description of Exhibit
   
10.1 Offer of Employment Letter, dated January 5, 2022, by and between Acreage Holdings, Inc. and Dennis Curran.
   
99.1 Press Release of Acreage Holdings, Inc. dated March 1, 2022 announcing appointment of Chief Operating Officer and Senior Leadership Update.
   
99.2 Press Release of Acreage Holdings, Inc. dated March 3, 2022 announcing appointment of Steve Strom to the Board of Directors
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
   

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

   
  ACREAGE HOLDINGS, INC.  
     
Date:  March 4, 2022 /s/ Steve Goertz                                                

Steve Goertz

Chief Financial Officer

 

 

 

Exhibit 10.1

 

January 5, 2022

 

Dennis Curran

77 Charlton Street Unit S3C

New York, NY 10014

 

Re: Offer of Employment

 

Dear Dennis:

 

1.Offer and Position

 

We are very pleased to extend an offer of employment to you for the position of Chief Operating Officer (“COO”) of Acreage Holdings, Inc. (the “Company”). Your employment is contingent upon the successful completion of a review of references and background checks and will be subject to the terms and conditions set forth in this letter (the “Offer Letter”). This Offer Letter will be binding upon execution (the “Execution Date”). The Board of Directors of the Company (“Board”) will take all such actions required for you to be appointed as COO as of the Start Date (as defined below).

 

2.Duties, Authority and Responsibilities

 

In your capacity as COO, you will have such duties, authorities and responsibilities as are (a) commensurate with such title (subject to oversight by the Chief Executive Officer (“CEO”) of the Company), (b) required of such position, and (c) assigned to you from time to time by the CEO that are reasonably consistent with your position. You will report directly to the CEO and will be subject to and comply with the Company’s written policies during your employment with the Company (including but not limited to policies related to prohibited harassment, discrimination, and retaliation, and prohibited insider trading). You agree to devote substantially all of your business time and attention to the performance of your duties; provided that (x) you shall not be precluded from engaging in civic, charitable or religious activities, (y) you shall not be precluded from serving on the board of directors of a corporation or similar governing body of another company that is not a competitor to the Company or its subsidiaries and that is approved in advance by the Board, provided however, that while you are COO you will not serve on more than one (1) other board of directors for any other for-profit business and may be required to resign from these boards in the event that such service interferes with your ability to perform the duties of COO for the Company , and (z) you shall not be precluded from managing your passive investments. Notwithstanding the foregoing, any outside activities must be in compliance with the Company’s policies, including its Code of Ethics, including approval procedures, and must not materially interfere with your duties as COO.

 

3.Start Date

 

Your start date will be March 1, 2022 (the “Start Date”).

 

 1 

 

 

4.Base Salary

 

In consideration of your services, you will be paid an initial base salary of $350,000 per year, subject to periodic reviews by the Compensation Committee of the Board (the “Committee”), as determined in its sole and absolute discretion, payable in accordance with the standard payroll practices of the Company and subject to all withholdings and deductions as required by law. Your initial base salary and any such adjustment in initial base salary shall constitute “Base Salary” for the purposes of this Offer Letter.

 

5.Annual Bonus Award

 

During your employment, you will be eligible to receive an annual bonus award, with terms and conditions approved by the Committee. Beginning in 2022, your target annual Short Term Incentive (“STI”) bonus award opportunity will be seventy-five percent (75%) of your base salary with the opportunity to go to one-hundred and fifty percent (150%) of your base salary if so approved by the Committee, based on the satisfaction of certain Company financial performance targets, subject to annual review by the Committee. The decision to provide any annual STI bonus and the amount and terms of any annual bonus award shall be in the sole and absolute discretion of the Committee. The Committee shall determine achievement of all of the financial performance targets for the annual bonus award along with the form of the award.

 

You will receive no bonus under this Section if you are not employed by the Company on the date the Committee finalizes the amount of and authorizes payment of the annual bonus award. The Company will have such authority to demand the repayment or “claw back” of any amounts paid pursuant to this opportunity as needed to comply with all applicable laws and regulations.

 

6.Equity Award

 

During your employment with the Company, you will be eligible to participate in the Acreage Holdings, Inc. annual Omnibus Equity Incentive Plan, as amended from time to time (the “Omnibus Plan”), and receive equity awards thereunder in the form as determined by the Committee, and subject to vesting and other conditions as set forth in the Omnibus Plan and the applicable award agreements.

 

Subject to approval by the Board, the Company will grant you an initial equity award under the Omnibus Plan (the “Equity Award”). The Equity Award will be granted on or about your Start Date and is intended to cover any equity award for 2022. The equity award will have a total value of up to $1,050,000, consisting of New Restricted Stock Units and Floating Restricted Stock Units (the “RSUs”) and New Options and Floating Options, (the “Options”). The amount and type of RSUs (New/Floating) and Options (New/Floating) shall be determined solely by the Board and shall be consistent with the type of award issued to the Executive Team of the Company.

 

The total number of shares of RSUs and Options subject to the Equity Award will be equal to (a) $1,050,000 divided by (b) the closing price of the Company’s Common Stock on the Canadian Securities Exchange on the Start Date. The Equity Award will vest annually in one-third increments on the first, second, and third anniversary of your Start Date, provided that you are still employed by the Company on such dates. The vesting of your RSUs may also have a performance component to be determined by the Board at the time your Equity Award is formally approved. The Options issued pursuant to the Equity Award will expire five years following the date of the grant.

 

 2 

 

 

The Equity Award will be granted under and subject to the terms of the Omnibus Plan and evidenced in writing by, and subject to the terms of the Options and RSU award agreements.

 

7.Minimization of Tax Consequences

 

The Company agrees to use commercially reasonable efforts in cooperation with you to minimize any tax consequences that you may have as a result of any compensation earned under this Offer Letter, including but not limited to the structure, transfer or payment of stock options or restricted stock units that you have earned or may earn in the future, provided however, that the Company shall not be required to take any actions that would result in an adverse tax, business, financial or other negative impact on the Company or an increase in cost for the Company, and further provided that the Company shall comply with all applicable laws, statutes, and regulations.

 

8.Other Benefits and Perquisites

 

Following the Start Date, you also will be eligible to participate in the employee benefit plans and programs generally available to the Company’s employees and consistent with such plans and programs of the Company as in effect as of the date hereof, including but not limited to medical, life and disability insurance, retirement, vacation/paid time off, fringe benefit, perquisite, business expense reimbursement and travel plans or programs, in accordance with and subject to eligibility and other terms and conditions of such plans and programs, as in effect from time to time. The Company reserves the right to amend, modify or terminate any of its benefit plans or programs at any time and for any reason except as set forth in this Offer Letter.

 

9.Withholding

 

All forms of compensation paid to you as an employee of the Company shall be less all applicable withholdings.

 

10.Termination Without Cause

 

If the Company terminates your employment without Cause (as defined below in this Section 10), then upon execution of a reasonable and customary separation agreement and general release of claims satisfactory to the Company (which shall be governed by New York law, and referred to as the “Release”), the Company shall provide you with the following severance benefits (the “Severance Benefits”), provided however, that your eligibility for the Severance Benefits will not be triggered until you have been employed with the Company for at least three (3) months:

 

 3 

 

 

(a) Severance Benefits. Commencing on the first payroll date following the effective date of the Release, the Company will pay Severance Benefits equal to your Base Salary for a period of twelve (12) months, payable in installments on the Company’s regular payroll dates, subject to required and authorized normal withholdings and deductions. Notwithstanding the foregoing, in the event that the period during which you can consider, adopt and/or revoke the Release shall cross calendar years, all payments made during such period shall accumulate and be made in the succeeding calendar year.

 

(b) Medical Benefits. If you timely elect continuation of medical coverage under the Consolidated Omnibus Budget and Reconciliation Act of 1985, as amended, or, if applicable, state insurances laws (collectively, “COBRA”), then, as part of your Severance Benefits, the Company will pay the employer portion of the premiums necessary to continue your medical coverage (including coverage for eligible dependents, if applicable) through the period starting on the termination date and ending on the earliest to occur of: (i) the one-year anniversary of your termination date, (ii) the date you and your eligible dependents, if applicable, become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. If you become eligible for coverage under another employer’s group health plan, you must notify the Company of such event.

 

(c) Outstanding Stock Options/RSU’s. Notwithstanding any other provision to the contrary, to the fullest extent permitted by applicable law, as part of your Severance Benefits, you shall have the right to exercise any vested Options or RSU’s for a period of twelve (12) months following a Termination of Service (as such term is defined in the Omnibus Plan); provided however, that in the event of a Change in Control (as such term is defined in the Omnibus Plan) during the Severance Period, your vested Options or RSU shall be treated in the same manner as other vested Options or RSUs issued and outstanding for other similarly situated active employees of the Company.

 

(d) Breach of Severance Obligations. If at any time while you are receiving Severance Benefits from the Company, you materially breach any contractual or other obligation to the Company (to be determined at the discretion of the Board), the Severance Benefits as described above shall immediately cease. Following termination of your employment, any benefits to which you may be entitled pursuant to the Company’s employee benefit plans and policies shall be determined and paid in accordance with the terms of such plans and policies, and you shall have no further right to receive any other compensation, or to participate in any other plan, arrangement or benefit, with respect to future periods after such termination.

 

(e) Cause. For purposes of this Section 10, “Cause” means any of the following: (i) you have engaged in acts of dishonesty, or acts of fraud or other unlawful behavior against or at the expense of the Company; (ii) you have been convicted of, or pleaded nolo contendere, to any felony or crime of moral turpitude; (iii) your gross negligence or willful misconduct in the performance of your duties to the Company; (iv) you have engaged in any conduct which materially and adversely affects the business affairs of the Company, or violates the policies of the Company; (v) you have refused to substantially perform your duties and responsibilities, or persistently neglect your duties, or experience chronic unapproved absenteeism, in each case which continues after you receive written notice thereof from the Company; (vi) your unauthorized disclosure of trade secrets or other confidential information of the Company; or (vii) you breach any fiduciary duty owed to the Company. The determination of whether “Cause” exists shall be made by the Board, and its determination shall be final, conclusive and binding.

 

 4 

 

 

11.At-will Employment

 

Your employment with the Company will be for no specific period of time. Rather, your employment will be at-will, meaning that you or the Board may terminate your employment relationship at any time, with or without cause, and with or without notice and for any reason or no particular reason. Nothing in this Offer Letter shall be construed to alter the at-will nature of your employment with the Company. Although your compensation and benefits may change from time to time, the at-will nature of your employment may only be changed by an express written agreement signed on behalf of the Company by an authorized officer of the Company. Upon the termination of your employment with the Company for any reason, you will immediately and without the need for any additional action be deemed to have resigned from all officer positions with the Company and any position you might then hold as a member of the governing boards of the Company.

 

12.Governing Law; Entire Agreement

 

This Offer Letter shall be governed by the laws of the State of New York, without regard to conflict of law principles. Unless specifically provided herein, this Offer Letter contains all of the understandings and representations between you and the Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter.

 

13.Indemnification

 

The Company shall defend, indemnify and hold you harmless to the maximum extent permitted by applicable law, against all claims, liabilities, costs, charges and expenses incurred or sustained by you in connection with any action, lawsuit, arbitration, mediation or other proceeding to which you may be made a party by reason of being an Officer, Director or employee of the Company, to the extent based on actions taken in the course and scope of your employment with the Company.

 

14.Mandatory Arbitration

 

Any dispute, controversy or claim arising out of or related to this Offer Letter or any breach of this Offer Letter, or arising out of or related to your employment with the Company, shall be submitted to and decided by mandatory binding arbitration administered under New York law and venued in New York City. You and the Company agree that each is giving up the right to a jury trial or to file a lawsuit in court against the other, as well as the right to bring a class or collective action against the other in court or in arbitration. The parties agree to jointly select a retired Judge as the single arbitrator, who shall have the power and authority, with the parties’ input, to set a schedule and process for pre-hearing and hearing matters. If the parties are unable to agree on an arbitrator, then the arbitration shall be administered by the American Arbitration Association and shall be conducted consistent with the rules, regulations and requirements thereof as well as any requirements imposed by state law. Any arbitral award determination shall be final and binding upon the parties.

 

 5 

 

 

15.Representations

 

You represent that you are not party to any agreement that would limit your ability to accept this Offer Letter and to discharge your duties to the Company.

 

16.Section 409A

 

The intent of the parties is that the payments and benefits under this Offer Letter comply with or be exempt from Section 409A of the Internal Revenue Code of 1986, as amended, and the rules and regulations and Internal Revenue Service notices thereunder, and accordingly, to the maximum extent permitted, this Offer Letter shall be interpreted to be in compliance therewith.

 

If any payment, compensation or other benefit provided to you under this Offer Letter in connection with your “separation from service” (within the meaning of Section 409A) is determined, in whole or in part, to constitute “nonqualified deferred compensation” within the meaning of Section 409A and you are a specified employee as defined in Section 409A(2)(B)(i), no part of such payments shall be paid before the day that is six months plus one day after the date of termination or, if earlier, ten (10) business days following your death (the “New Payment Date”). The aggregate of any payments and benefits that otherwise would have been paid and/or provided to you during the period between the date of termination and the New Payment Date shall be paid to you in a lump sum on such New Payment Date. Thereafter, any payments and/or benefits that remain outstanding as of the day immediately following the New Payment Date shall be paid without delay over the time period originally scheduled, in accordance with the terms of this Offer Letter. Notwithstanding anything to the contrary herein, to the extent that the foregoing delay applies to the provision of any ongoing welfare benefits, you shall pay the full cost of premiums for such welfare benefits due and payable prior to the New Payment Date and the Company will pay you an amount equal to the amount of such premiums which otherwise would have been paid by the Company during such period within five (5) business days following its conclusion.

 

A termination of employment shall not be deemed to have occurred for purposes of any provision of this Offer Letter providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A, and for purposes of any such provision of this Offer Letter, references to a “resignation,” “termination,” “terminate,” “termination of employment” or like terms shall mean separation from service.

 

All expenses or other reimbursements as provided herein shall be payable in accordance with the Company’s policies in effect from time to time, but in any event shall be made on or prior to the last day of the taxable year following the taxable year in which you incurred the expenses. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A: (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit; and (ii) the amount of expenses eligible for reimbursements or in-kind benefits provided during any taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other taxable year.

 

 6 

 

 

For purposes of Section 409A, your right to receive any installment payments pursuant to this Offer Letter shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Offer Letter specifies a payment period with reference to a number of days (e.g., payment shall be made within 30 days following the date of termination), the actual date of payment within the specified period shall be within the sole discretion of The Company.

 

If you wish to accept this position, please sign below and return this Offer Letter to me within 5 days. This offer is open for you to accept until January 14, 2022, at which time it will be deemed to be withdrawn.

 

  Sincerely,  
     
  Acreage Holdings, Inc.  
     
  By: /s/ Peter Caldini  
  Name: Peter Caldini  
  Title: Chief Executive Officer  

 

 

Acceptance of Offer

 

I have read, understood and accept all the terms of this Offer Letter. I have not relied on any agreements or representations, express or implied, with respect to such employment which are not set forth expressly in this Offer Letter or in the documents referred herein, and this Offer Letter supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to my employment by the Company.

 

/s/ Dennis Curran  
Dennis Curran  
   
1/5/2022  
Date  

 

 7 

 

 

Exhibit 99.1

 

Acreage Appoints Chief Operating Officer and Announces Senior Leadership Update

 

Dennis Curran, former GSK & P&G Executive, named COO of Acreage

New York, NY - March  1, 2022 - Acreage Holdings, Inc. (“Acreage” or the “Company”) (CSE: ACRG.A.U, ACRG.B.U), (OTCQX: ACRHF, ACRDF), a vertically integrated, multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., today announced the appointment of Dennis Curran as the Company’s Chief Operating Officer (“COO”). The Company also announced the resignation of James Doherty, General Counsel, effective April 30, 2022, and has launched a national search for his successor.

 

“Over the last year, we have made significant strides to strengthen our management team, and today we further these efforts with the addition of Dennis as our new COO,” said Peter Caldini, CEO of Acreage Holdings. “Dennis has a distinguished track record leading consumer-focused businesses through operational growth strategies, and we are confident he brings the right skill set to us as we capitalize on the excellent work our team accomplished over the last year. We are excited for all the opportunities this new year will bring us and we welcome Dennis to the Acreage family.”

Dennis Curran, COO of Acreage, said: “I’m thrilled to be joining the Acreage team at such an exciting time. The Company has done phenomenal work over the last year to become profitable and to reposition the business for growth in several key markets. I look forward to contributing to the future success of Acreage.”

 

Dennis Curran brings over 35 years of leadership experience in the areas of product categories, sales, trade channels, distributor management, marketing, and business maturity in both domestic and international markets. Before joining Acreage, he was the Chief Customer Officer at GSK Consumer Healthcare and was responsible for delivering sales, profitability, and innovation for the United States, the business’ largest market.  Prior to GSK, Mr. Curran had a career spanning 29 years with Procter and Gamble (P&G) in both the US and Europe working with some of the world’s leading consumer brands.  His last role at P&G was Regional Manager and President for P&G’s North American Prestige business. Mr. Curran was responsible for overseeing sales, marketing, operations, and communications for various prestige brands with a portfolio worth roughly $550 million.  Dennis will be replacing Robert J. Daino who as previously announced will be retiring at the end of March.

 

Mr. Caldini concluded, “On behalf of the Acreage family, I also would like to thank Jim Doherty for all his hard work over the past four years and wish him the best as he returns to private practice. Jim has been a key player in Acreage’s growth, overseeing acquisitions, mergers, and compliance, and assisting in raising significant funding. We are all grateful for the diligence and enthusiasm he brought in helping to transform this company into what it is today.”

 

 1

 

 

 

About Acreage Holdings, Inc.

 


Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company’s national retail store ‎brand, The Botanist. With its principal address in New York City, Acreage’s wide range of national and regionally available cannabis products include the award-winning The Botanist brand, the premium brand Superflux in Illinois, Massachusetts, and Ohio, the Tweed brand, the Prime medical brand in Pennsylvania, the Innocent brand in Illinois, and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing, and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a seamless, consumer-focused, branded experience. Learn more at www.acreageholdings.com and follow us on Twitter, LinkedIn, Instagram, and Facebook.

 

For more information and documents related to the Acreage, please visit: https://investors.acreageholdings.com

 

For more information, contact:

 

Steve Goertz

Chief Financial Officer

investors@acreageholdings.com

 

Courtney Van Alstyne

MATTIO Communications

ir@mattio.com

 

 2

 

 

Exhibit 99.2

 

Acreage Appoints Steve Strom to its Board of Directors

 

Seasoned finance executive with over 30 years of strategic advisory experience selected as Independent Director

 

New York, NY - March 4, 2022 - Acreage Holdings, Inc. (“Acreage”) (CSE: ACRG.A.U, ACRG.B.U), (OTCQX: ACRHF, ACRDF), a vertically integrated, multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., today announced the appointment of Steve Strom to its Board of Directors, effective immediately. Mr. Strom is the ninth member of Acreage’s Board of Directors and will serve as the Chair of the Audit Committee.

 

“Steve has an impressive track record of positioning companies for success in both operationally and financially complex market environments, and we are thrilled to welcome him to our Board of Directors,” said Peter Caldini, CEO of Acreage Holdings. “His decades-long corporate advisory experience and strong financial acumen will be a significant asset to us as we drive continued profitability and execute on our refocused strategy to deliver long-term value for our shareholders.”

 

Mr. Strom holds over 30 years of strategic advisory and investment banking experience, guiding companies, their boards, and key stakeholders through special situations. Over the course of his career, he worked with businesses across a wide range of sectors advising on M&A, financings, corporate restructurings, and other transformational challenges. Currently, Mr. Strom serves as CEO and Founder of Odinbrook Global Advisors, an independent advisory firm focused on restructuring distressed companies.

 

“I am excited to join Acreage at such a critical point in Acreage’s evolution and look forward to working alongside such an esteemed group of individuals to support the next phase of growth,” said Mr. Strom.

 

Prior to founding Odinbrook Global Advisors, Mr. Strom was CEO of Blackhill Partners, an independent investment bank specializing in special situations and bankruptcy. He previously served as Managing Director at Chanin Capital Partners (a restructuring advisory boutique acquired by global management consulting firm Kroll), CIBC World Markets and was Global Head of Restructuring at Jefferies. He began his career in finance with Chemical Bank, now known as JPMorgan Chase, and. Mr. Strom holds a Bachelor’s Degree in Business (Finance) from Arizona State University and an MBA from University of Michigan. He also served as an Independent Director for the Board of Nasdaq-listed Schmitt Industries.

 

 1

 

 

 

About Acreage Holdings, Inc.

 

Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company’s national retail store ‎brand, The Botanist. With its principal address in New York City, Acreage’s wide range of national and regionally available cannabis products include the award-winning The Botanist brand, the craft brand Superflux, the Tweed brand, the Prime medical brand in Pennsylvania, the Innocent brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing, and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a seamless, consumer-focused, branded experience. Learn more at www.acreageholdings.com and follow us on Twitter, LinkedIn, Instagram, and Facebook.

 

For more information, contact:

 

Steve Goertz

Chief Financial Officer

investors@acreageholdings.com

 

Courtney Van Alstyne

MATTIO Communications

ir@mattio.com

 

# # #

 

 2